P2.01-37 A Ph 1/2 Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) with Docetaxel in pts with Previously Treated NSCLC
- Resource Type
- Abstract
- Source
- In
Journal of Thoracic Oncology October 2018 13(10) Supplement:S679-S679 - Subject
- Language
- ISSN
- 1556-0864